Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC® Protein Degrader Development Prog...
December 11 2020 - 4:15PM
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology
company creating a new class of drugs based on targeted protein
degradation, today announced that it will host a live webcast
presentation on Monday, December 14, 2020 at 8:00 a.m. ET to
provide clinical program updates for its PROTAC® protein degraders
ARV-471 and ARV-110. The presentation will include updates from the
Phase 1 dose escalation studies of ARV-471 in patients with locally
advanced or metastatic ER positive / HER2 negative breast cancer
and ARV-110 in men with metastatic castrate-resistant prostate
cancer. The event will also include an overview of the recently
initiated Phase 2 dose expansion study for ARV-110.
The live webcast presentation will be available here or on
the Company’s website at www.arvinas.com under Events +
Presentations. To access the event via dial-in, please dial (844)
467-7654 (domestic) or (602) 563-8497 (international) and refer to
conference ID 9681734. A replay of the webcast will be archived on
the Arvinas website following the presentation.
About ArvinasArvinas is a clinical-stage
biopharmaceutical company dedicated to improving the lives of
patients suffering from debilitating and life-threatening diseases
through the discovery, development, and commercialization of
therapies that degrade disease-causing proteins. Arvinas uses its
proprietary PROTAC® Discovery Engine platform to engineer
proteolysis targeting chimeras, or PROTAC® targeted protein
degraders, that are designed to harness the body’s own natural
protein disposal system to selectively and efficiently degrade and
remove disease-causing proteins. In addition to its robust
preclinical pipeline of PROTAC® protein degraders against validated
and “undruggable” targets, the company has two clinical-stage
programs: ARV-110 for the treatment of men with metastatic
castrate-resistant prostate cancer; and ARV-471 for the treatment
of patients with locally advanced or metastatic ER+/HER2- breast
cancer. For more information, visit www.arvinas.com.
Contacts for Arvinas
InvestorsWill O’Connor, Stern Investor
Relations ir@arvinas.com
MediaKirsten Owens, Arvinas
Communicationskirsten.owens@arvinas.com
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Apr 2023 to Apr 2024